In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective.
The new agent is a gallium-68 (Ga-68)-labeled peptide BBN-RGD agent that targets both gastrin-releasing peptide receptor (GRPR) and integrin ?v?3. Dual-receptor targeting provides advantages over single-receptor targeting by allowing tumor contrast when either or both receptor types are expressed, improving binding affinity and increasing the number of effective receptors.
Approximately one in seven men will be diagnosed with prostate cancer in his lifetime. In 2017, the American Cancer Society estimates that there will be more than 161,000 new prostate cancer cases in the United States and around 27,000 deaths from the disease. “Although treatable at the early stage, prostate cancer is prone to metastasis,” explain the team of authors, led by Xiaoyuan Chen, senior investigator, Laboratory of Molecular Imaging and Nanomedicine at the U.S. National Institute of Biomedical Imaging and Bioengineering. “An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer.”
This study included 13 patients with prostate cancer (four newly diagnosed and nine post-therapy) and five healthy volunteers. Ga-68-BBN-RGD PET/CT detected 20 bone lesions in seven patients either with primary prostate cancer or after radical prostatectomy. The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. “This result is better than bone scanning with MDP,” Chen notes, referring to the most common radiotracer used today. “MDP bone scans are sensitive but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in the case of trauma and infection.” No adverse side effects were found during the whole procedure and two-week follow-up, demonstrating the safety of Ga-68-BBN-RGD.
“Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors,” explains Chen.
Looking ahead, Chen says, “Ga-68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.” He points out that larger-scale clinical investigations are warranted.
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Bill Turnbull says he ignored prostate cancer symptoms as he urges men to get checkedon November 27, 2020 at 4:37 am
Bill Turnbull has revealed he ignored symptoms before being diagnosed with terminal prostate cancer. The broadcaster, 64, was told by doctors in 2017 that he had incurable prostate cancer, which has ...
- Al Roker co-hosts Thanksgiving Day parade after prostate cancer surgeryon November 26, 2020 at 9:50 am
Al Roker joined his “Today” show colleagues on Thursday to help co-host Macy’s Thanksgiving Day Parade, following his prostate cancer surgery earlier this month. Taking to Instagram, 66-year-old Roker ...
- Prostate cancer: Pain in testicles could indicate the cancer has spreadon November 26, 2020 at 8:55 am
PROSTATE cancer is the most common cancer in men in the UK, with around 40,000 men diagnosed with prostate cancer every year in England alone. Symptoms can take years to surface and sadly when they do ...
- Bill Turnbull, 64, emotionally urges men to get prostate exams amid his terminal cancer battleon November 26, 2020 at 4:22 am
Bill Turnbull has emotionally urged men to go for prostate exams amid his battle with terminal cancer. The broadcaster, 64, who was diagnosed with incurable prostate cancer in 2017, spoke to Gethin ...
- RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDAon November 24, 2020 at 10:56 pm
RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug ...
- Medical mistrust can make African Americans to regret their choice of treatment for prostate canceron November 24, 2020 at 9:57 pm
Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer.
- For African American men with prostate cancer, decision regret linked to medical mistruston November 24, 2020 at 12:43 pm
Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer, suggests a study in The Journal of Urology, Official ...
- Genetic Signature Could Predict Prostate Cancer Metastasison November 24, 2020 at 7:03 am
The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.
- Rapid Rise in Cases of Prostate Cancer Worldwide to Influence Growth of Prostate Cancer Therapeutics Market to a Great Extent: TMRon November 24, 2020 at 5:30 am
The prevalence of prostate cancer is magnifying across the world at a rapid rate. According to the estimates by the American Cancer ...
via Bing News